Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical Testing in a Number of Indications Including Microcystic Lymphatic Malformations and Venous Malformations, among others ...
Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the ...
DURHAM, N.C., March 17, 2026 - MedPharm, a global leader in topical and transdermal contract drug development and ...
Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.
For most broken bones, bone cells regrow on their own while patients wear a cast or brace to keep the injury steady. But for complex or severe fractures, surgeons may intervene by placing grafts or ...
Clinical Testing in a Number of Indications Including Microcystic Lymphatic Malformations and Venous Malformations, among others to Commence 1H 2026 Dr. Michael Myers, Chief Executive Officer of Quoin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results